Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenativ in congenital antithrombin deficiency during surgery or delivery
2024-515830-34-00Phase 3Authorised
- Sponsor
- Octapharma
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, open-label trial of antithrombin III concentrate in congenital antithrombin deficiency (ATD) (2 arms), sponsored by Octapharma. Primary endpoint: Incidence of composite thromboembolic events. Planned start Oct 2024; status: authorised.
02
Drugs
antithrombin III concentrate
03
Conditions
congenital antithrombin deficiency (ATD)
Beyond the preview
Go deeper on 2024-515830-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515830-34-00.